Investor Resources


SEDAR (the System for Electronic Document Analysis and Retrieval) is the system used for electronically filing most securities related information with the Canadian securities regulatory authorities. Filing with SEDAR started January 1, 1997, and is now mandatory for most reporting issuers in Canada. Information on the rules for electronic filing can be found in SEDAR Rules and Forms.

The SEDAR system enables industry to file securities documents and remit filing fees electronically -- saving time and money. The SEDAR system allows users to gain immediate and intelligent access to issuer information in the public domain, and provides an important communications link among issuers, filers and the securities regulatory authorities.

Information about Nova Mentis Life Science

Corporate Info


Visit Our CSE Page


Transfer Agent: Computershare
Tel: 604-661-9400

Auditor: Smythe LLP
Tel: 604-687-1231

Legal Counsel:Richards Buell Sutton LLP
Tel: 604-682-3664
Web: https://www.rbs.ca/

Corporate Presenation

Nova Mentis Life Science Corp.


A Canadian-based public company that builds and supports a diversified portfolio of health and wellness businesses. Aiming to be an industry leader in the development of objective biologic endpoints to validate subjective behavioral changes in people receiving psychedelic therapy.

Read Corporate Presentation

Join our Newsletter

With every issue we'll keep you posted on information and events that are important to the Life Science sector - as well as what is happening here at Nova Mentis Life Science.

Contact Investor Relations

Any investor relations inquiries can be directed to info@novamentis.ca

Contact Investor Relations



Dr. Hausman at Fragile-X Conference


18th NFXF International Fragile X Conference

Dr. Marvin S. Hausman, the Chairman of Nova’s Scientific Advisory Board, delivered a presentation titled: A Novel Psilocybin Microdose Treatment of Fragile X Syndrome at the 18th NFXF International Fragile X Conference in July 2022.

Nova’s recent research results showed that a very low microdose formulation of our proprietary psilocybin drug (NM-1001) significantly modulated behavioural and cognitive defects in a genetic model of FXS.



Stock Performance

Canada/CSE - Stock Quote